Literature DB >> 23361608

Industry pulse : editorial development by adis international limited, Italy.

.   

Abstract

Year:  2005        PMID： 23361608     DOI： 10.2165/00151642-200512030-00174

Source DB:  PubMed          Journal:  High Blood Press Cardiovasc Prev        ISSN： 1120-9879


× No keyword cloud information.
  17 in total

1.  Morning surge and variability in blood pressure: a new therapeutic target?

Authors:  Kazuomi Kario
Journal:  Hypertension       Date:  2005-02-21       Impact factor: 10.190

2.  Angiotensin II inhibition and prevention of atrial fibrillation and stroke.

Authors:  Martial G Bourassa
Journal:  J Am Coll Cardiol       Date:  2005-03-01       Impact factor: 24.094

Review 3.  Atrial fibrillation.

Authors:  S M Narayan; M E Cain; J M Smith
Journal:  Lancet       Date:  1997-09-27       Impact factor: 79.321

4.  Circadian variation in the timing of stroke onset: a meta-analysis.

Authors:  W J Elliott
Journal:  Stroke       Date:  1998-05       Impact factor: 7.914

5.  Regression of carotid atherosclerosis by control of morning blood pressure peak in newly diagnosed hypertensive patients.

Authors:  Raffaele Marfella; Mario Siniscalchi; Francesco Nappo; Pasquale Gualdiero; Katherine Esposito; Ferdinando Carlo Sasso; Federico Cacciapuoti; Clara Di Filippo; Francesco Rossi; Michele D'Amico; Dario Giugliano
Journal:  Am J Hypertens       Date:  2005-03       Impact factor: 2.689

6.  The Losartan Intervention For Endpoint reduction (LIFE) in Hypertension study: rationale, design, and methods. The LIFE Study Group.

Authors:  B Dahlöf; R Devereux; U de Faire; F Fyhrquist; T Hedner; H Ibsen; S Julius; S Kjeldsen; K Kristianson; O Lederballe-Pedersen; L H Lindholm; M S Nieminen; P Omvik; S Oparil; H Wedel
Journal:  Am J Hypertens       Date:  1997-07       Impact factor: 2.689

7.  Trandolapril reduces the incidence of atrial fibrillation after acute myocardial infarction in patients with left ventricular dysfunction.

Authors:  O D Pedersen; H Bagger; L Kober; C Torp-Pedersen
Journal:  Circulation       Date:  1999-07-27       Impact factor: 29.690

8.  Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study.

Authors:  Kristian Wachtell; Björn Hornestam; Mika Lehto; David J Slotwiner; Eva Gerdts; Michael H Olsen; Peter Aurup; Björn Dahlöf; Hans Ibsen; Stevo Julius; Sverre E Kjeldsen; Lars H Lindholm; Markku S Nieminen; Jens Rokkedal; Richard B Devereux
Journal:  J Am Coll Cardiol       Date:  2005-03-01       Impact factor: 24.094

Review 9.  Angiotensin II receptor antagonists.

Authors:  M Burnier; H R Brunner
Journal:  Lancet       Date:  2000-02-19       Impact factor: 79.321

10.  Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol.

Authors:  Björn Dahlöf; Richard B Devereux; Sverre E Kjeldsen; Stevo Julius; Gareth Beevers; Ulf de Faire; Frej Fyhrquist; Hans Ibsen; Krister Kristiansson; Ole Lederballe-Pedersen; Lars H Lindholm; Markku S Nieminen; Per Omvik; Suzanne Oparil; Hans Wedel
Journal:  Lancet       Date:  2002-03-23       Impact factor: 79.321
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.